Adipose-Derived Regenerative Cells
Phase 2Small molecule
Adipose-Derived Regenerative Cells is one of 53 small molecule programs targeting Rotator Cuff Tear. It is currently in Phase 2.
3
Indications
5
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Remodulin
United TherapeuticsApproved
Desferal
Jazz PharmaceuticalsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Esbriet
LLegacy Health System
Approved
Inomax
MMallinckrodt
Approved
Tobrex
VViatris Specialty LLC
Approved
Nitrostat
VViatris Specialty LLC
Approved
Mozobil
GGenzyme, a Sanofi Company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rotator Cuff Tear1 trial
Stem Cells1 trial
Diabetic Foot1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OOdense University Hospital